Takeda H1 Net Profit Surges 171.8%, Revenue Up 8.4%; Raises FY2026 Outlook on FX Tailwind

Takeda Pharmaceutical Co. (TAK) reported first-half net profit of JPY305.63 billion, or JPY193 per share, up 171.8% from JPY112.44 billion, or JPY72 per share, a year earlier. Revenue rose 8.4% to JPY2.41 trillion from JPY2.22 trillion. Citing foreign exchange benefits, the company raised its full-year 2026 outlook to profit of JPY209 billion, earnings per share of JPY131 and revenue of JPY4.7 trillion. Takeda cited regulatory progress during the period, including U.S., Japan and China approval of ORZEYFUL (oveporexton), the U.S. launch of MIMRYLO (rusfertide) and advancement in the review of zasocitinib, alongside added late-stage pipeline data. Takeda shares closed Wednesday on the NYSE at $20.15, down 0.59%, and closed Thursday on the Tokyo Stock Exchange at JPY6,471, up 2.60%.